Xiromed has announced the introduction of the first generic rival to the Taytulla contraceptive in the US. The launch of Gemmily represents the latest new product for the Insud subsidiary following a busy year.
Insud Pharmaceuticals subsidiary Xiromed has launched the first generic rival to AbbVie’s Taytulla (norethindrone acetate/ethinyl estradiol capsules and ferrous fumarate capsules) 1mg/20mcg contraceptive in the US, under the name of Gemmily, upon US Food and Drug Administration approval.
“The launch of this first-to-market generic is an important milestone for Xiromed,” said Xiromed CEO Narasimhan Mani, “demonstrating the strength...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
An abbreviated licensure pathway for biologics was created by the 2009 Biologics Price Competition and Innovation Act. Biologics demonstrated to be biosimilar to or interchangeable with FDA-approved products can use the 351(k) biologics license application pathway. Biosimilars BLAs submitted under the 351(k) pathway have a 12 month user fee goal for FDA action. Updated weekly.
Amneal has marked its entry into China after receiving its first product approval in the market. Meanwhile, the firm has also outlined US approvals for two generics currently suffering from shortages.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
